

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior version, and lists, of claims in the application:

Listing of Claims:

Claim 1-8. (Previously Cancelled)

Claim 9. (Previously Presented) A controlled-release dosage form for the oral delivery of 1-[2-dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol or its pharmaceutically acceptable salts to a patient, wherein the dosage form comprises:

- (a) a wall comprising a semipermeable composition permeable to the passage of fluid, but not to 1-[2-dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol or its pharmaceutically acceptable salts, which wall surrounds;
- (b) a compartment;
- (c) a therapeutic composition in the compartment comprising 1-[2-dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol or its pharmaceutically acceptable salts;
- (d) a displacement composition in the compartment comprising an osmotically effective compound; and
- (e) an exit passageway in the dosage form for delivering the 1-[2-dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol from the dosage form in a controlled-release manner.

Claims 10-14. (Previously Cancelled)

Claim 15. (Previously Presented) A sustained-release dosage form for the oral delivery of 1-[2-dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol or its pharmaceutically acceptable salts to a patient, wherein the dosage form comprises:

- (a) a wall comprising a semipermeable composition permeable to the passage of fluid, but not to 1-[2-dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol or its pharmaceutically acceptable salts, which wall surrounds;
- (b) a compartment;

- (c) a therapeutic composition in the compartment comprising 1-[2-dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol or its pharmaceutically acceptable salts;
- (d) a displacement composition in the compartment comprising an osmotically effective compound; and
- (e) an exit passageway in the dosage form for delivering the 1-[2-dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol from the dosage form in a sustained-release manner.

Claim 16. (New) The controlled-release dosage form in claim 9 wherein the therapeutic composition in the compartment comprises about 150 mg or less of 1-[2-dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol or its pharmaceutically acceptable salts.

Claim 17. (New) The controlled-release dosage form in claim 9 wherein the therapeutic composition in the compartment comprises approximately 75 mg or less of 1-[2-dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol or its pharmaceutically acceptable salts.

Claim 18. (New) The controlled-release dosage form in claim 9 wherein the therapeutic composition in the compartment comprises about 40 mg or less of 1-[2-dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol or its pharmaceutically acceptable salts.

Claim 19. (New) The sustained-release dosage form in claim 15 wherein the therapeutic composition in the compartment comprises about 150 mg or less of 1-[2-dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol or its pharmaceutically acceptable salts.

Claim 20. (New) The sustained-release dosage form in claim 15 wherein the therapeutic composition in the compartment comprises about 75 mg or less of 1-[2-dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol or its pharmaceutically acceptable salts.

Claim 21. (New) The sustained-release dosage form in claim 15 wherein the therapeutic composition in the compartment comprises about 40 mg or less of 1-[2-dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol or its pharmaceutically acceptable salts.